Health
From The Report: Indonesia 2015
View in Online Reader

The year 2015 marks the second year of the roll out of universal health care in Indonesia. The plan saw a challenging launch in 2014, but administrators and lawmakers are continuing to work toward the target of full implementation by 2019. As more people seek health care because they have coverage, more hospitals are needed, as are more medical staff. Analysts blame regulation disparities, poor health care infrastructure and an urban-rural gap in the number of medical staff attending to each region for the potential difficulty in meeting the 2019 deadline. However, having made universal health care a top priority, the government is determined to overcome these challenges.

This chapter contains a dialogue with Jorge Wagner, President-Director, Boehringer Ingelheim Indonesia, and Bernadette Ruth Irawati Setiady, President-Director, Kalbe Pharma; and an interview with Andi Wijaya, Chairman, Prodia.

Articles from this Chapter

Overview

Indonesia’s universal health care goals
OBG
plus

The year 2015 marks the second year of the rollout of universal health care (UHC), known as JKN locally, in Indonesia. The plan saw a challenging launch in 2014, but administrators and lawmakers are maintaining the target of full implementation by 2019, when 240m260m Indonesians will be eligible for coverage under the plan. In many ways, the implementation of JKN is driving the rest of the country’s health sector, as a new model of supply and demand emerges. As more people seek health care because…

Analysis

Market for machines grows in Indonesia’s health care sector
OBG
plus

Because Indonesia manufactures only a small number of the high-tech medical devices and equipment it uses domestically, the opportunities for foreign manufacturers, suppliers and distributors of medical devices are numerous. Devices and equipment used in clinical laboratories, diagnosis, surgery, cancer treatment, dental services and dermatology are all expected to see high demand as the nation’s Health Care and Social Security Agency (BPJS) is embraced by patients, clinics and hospitals. As the…

Analysis

Ensuring intellectual property protection and quality assurance in Indonesia’s pharmaceuticals sector
OBG
plus

The introduction of universal health care is expected to have a major impact on Indonesia’s already thriving pharmaceuticals sector. Analysts have predicted that 2015 will be a watershed year for pharmaceuticals, with the full implementation of universal health care (known as JKN locally) expected to increase demand for prescription medications. Generics especially will benefit, because the government relies on them to keep costs under control. JKN is again the driver of this trend, as it covers…

Overview

OBG talks to Jorge Wagner, President-Director, Boehringer Ingelheim Indonesia; and Bernadette Ruth Irawati Setiady, President-Director, Kalbe Farma
OBG
plus

Interview: Jorge Wagner, Bernadette Ruth Irawati Setiady Indonesia’s pharmaceutical market is expected to reach $9.9bn by 2020. What growth is expected for high-end drugs vis-à-vis generics? JORGE WAGNER: While generics are experiencing strong growth following expanded access to medicines with the implementation of the universal health care scheme, there is also a place for innovative products within this scheme and in the private sector. Developing innovative drugs and therapies that can provide…

Interview

Andi Wijaya, Chairman, Prodia: Interview
OBG
plus

Interview:Andi Wijaya Which areas within Indonesia’s health sector currently offer the most opportunities for investment? ANDI WIJAYA: There is a lot of interest in developing new hospitals, as Indonesia’s universal health care programme is expected to put pressure on the public hospital system. Investors are therefore looking to develop private medical facilities as an alternative for the growing middle class. Also, an increase in purchasing power in the middle class is driving Indonesians…